EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease

Matteo Bramuzzo iD, Fabiola Giudici, Serena Arrigo, Paolo Lionetti iD, Giovanna Zuin, Claudio Romano, Francesco Graziano iD, Simona Faraci, Patrizia Alvisi, Sara Signa, Luca Scarallo, Stefano Martelossi und 1 weitere

Inflammatory Bowel Diseases · 05.01.2024 · 30 (1) · 20-28

DOI: 10.1093/ibd/izad018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 17.02.2023. Verfasst von Matteo Bramuzzo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy. Hauptthemen laut MEDLINE: Thalidomide, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few drugs have been studied for patients with very early onset inflammatory bowel disease (VEOIBD). This study aimed to evaluate the efficacy and tolerance of thalidomide in children with VEOIBD compared with children with pediatric-onset IBD (pIBD).

Methods

A retrospective cohort study with a control group was conducted. Propensity score 1:1 matching was used to identify control subjects. The treatment persistence; the causes of drug withdrawal; the rate of clinical remission and mucosal healing at 1, 2, and 3 years; and adverse events (AEs) were evaluated in children with VEOIBD treated with thalidomide and compared with children with pIBD.

Results

Thirty-nine courses of treatment with thalidomide in VEOIBD and pIBD patients were compared. The treatment persistence at 1, 2, and 3 years was 68.2% (95% confidence interval [CI], 50.8%-80.6%), 57.0% (95% CI, 39.6%-71.1%), and 50.9% (95% CI, 33.7%-65.8%) for VEOIBD patients and 81.7% (95% CI, 65.3%-90.9%), 60.0% (95% CI, 41.7%-74.3%) and 33.0% (95% CI, 17.4%-49.5%) for pIBD patients, respectively (P = .12). A significantly higher proportion of VEOIBD patients discontinued therapy due to lack of efficacy (48.2% vs 17.2%; P = .03), while AEs were the main reason for discontinuation in pIBD patients. Clinical remission and mucosal healing rates did not significantly differ between VEOIBD and pIBD patients. A significatively lower number of VEOIBD patients experienced AEs compared with pIBD patients (14 [35.9%] vs 30 [76.9%]; P = .0005).

Conclusions

Thalidomide is an effective and tolerated treatment in children with VEOIBD. Discontinuation due to lack of efficacy is more frequent, but AEs are less common than in children with pIBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideInflammatory Bowel DiseasesChildHumansRetrospective StudiesAge of OnsetDrug Tolerance

Stichwörter der Autor:innen

childreninflammatory bowel diseasethalidomidetherapyvery early onset

Substanzen

Thalidomide

Autor:innen und Institutionen

  • Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
  • Bureau de biostatistique et d'épidemiologie, Gustave Roussy and Université Paris-Saclay, Paris, France.
  • Pediatric Gastroenterology and Endoscopy, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Department NEUROFARBA, Meyer Children's Hospital, University of Florence, Florence, Italy.
  • Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood G. Barresi, University of Messina, Messina, Italy.

ORCID-Profile: Matteo Bramuzzo, Paolo Lionetti, Francesco Graziano

Zitieren

APA

Bramuzzo, M., Giudici, F., Arrigo, S., Lionetti, P., Zuin, G., Romano, C., Graziano, F., Faraci, S., Alvisi, P., Signa, S., Scarallo, L., Martelossi, S., & Di Leo, G. (2024). Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 30(1), 20-28. https://doi.org/10.1093/ibd/izad018

Vancouver

Bramuzzo M, Giudici F, Arrigo S, Lionetti P, Zuin G, Romano C, et al. Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2024;30(1):20-28. doi:10.1093/ibd/izad018

BibTeX
@article{Bramuzzo2024,
  author = {Bramuzzo, Matteo and Giudici, Fabiola and Arrigo, Serena and Lionetti, Paolo and Zuin, Giovanna and Romano, Claudio and Graziano, Francesco and Faraci, Simona and Alvisi, Patrizia and Signa, Sara and Scarallo, Luca and Martelossi, Stefano and Di Leo, Grazia},
  title = {Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {1},
  pages = {20--28},
  doi = {10.1093/ibd/izad018}
}
Kostenlos starten →